Luca Giani Presents Ilios Therapeutics' Science and Strategy at the Biotech Showcase during the JP Morgan Conference
San Francisco - January 11th, 2023
Luca Giani, Cofounder and CEO of Ilios Therapeutics, presented the Company's cutting-edge science and strategy today at the Biotech Showcase in San Francisco as part of the annual J.P. Morgan biotech conference. The conference, which is one of the busiest weeks in healthcare, attracts a diverse range of attendees including general attendees, investors, presenting companies, seed-stage companies, sponsors, and members of the press.
This year, the Biotech Showcase gave attendees the opportunity to connect with their peers in-person in San Francisco. Investors had the chance to find investment opportunities, with participating companies ranging from early, mid to later stage, across sectors such as biotech and large pharma.
Ilios Therapeutics, a presenting company, showcased their innovative approach to addressing multiple pathways in neurodegenerative diseases. Their multi-targeted small molecules and AI-Driven Drug Discovery platform are a game-changing alternative to current treatments in development, and were well received by the audience. Seed-stage companies, in particular, found the conference to be crucial for meeting the right investors and getting in front of decision-makers during the most mportant fund-raising week of the year. The Seed Showcase provided a platform for
these companies to present their innovations and attract potential investors. Sponsors also had the opportunity to position their companies among the innovators of the life science industry through a sponsorship package that improved their visibility with prospective partners through digital solutions.
The Biotech Showcase in San Francisco was a great success and we were honored to be part of it. We look forward to continuing to share our cutting-edge science and strategy with the industry and making a positive impact on the lives of patients with neurodegenerative diseases.